Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 37.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.405%)
Open: 38.00
High: 38.00
Low: 38.00
Prev. Close: 38.00
MIG1 Live PriceLast checked at -
Maven Income and Growth VCT is an Investment Trust

To achieve long term capital appreciation and generate maintainable levels of income for shareholders through investing in small and medium sized unlisted and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

18 Oct 2023 15:54

RNS Number : 5721Q
Maven Income & Growth VCT PLC
18 October 2023
 

Maven Income and Growth VCT PLC

 

Interim results for the six months ended 31 August 2023 (unaudited)

 

The Directors are pleased to announce the unaudited Interim Management Report for the six months ended 31 August 2023.

 

Highlights

 

· NAV total return at 31 August 2023 of 146.28p per share

 

· NAV at 31 August 2023 of 40.87p per share, after payment of the 2023 final dividend of 1.15p per share in July 2023

 

· Interim dividend of 1.00p per share declared for payment on 1 December 2023

 

· Two new private companies and one AIM quoted holding added to the portfolio, with follow-on funding provided to seven portfolio companies

 

· Post the period end, two new private company investments completed

 

· Offer for Subscription closed, raising £6.74 million, with a new fund raising launched in October 2023

 

Overview

 

During the first half of the financial year, the macroeconomic environment remained challenging with growth prospects suppressed by inflationary pressures and rising interest rates. Against this backdrop, it is encouraging to report on the strategic progress that has been achieved by your Company. Whilst NAV total return has reduced modestly, compared to the position at the previous year end, most companies in the unlisted portfolio have continued to deliver revenue growth and achieve their commercial milestones. Notably, the performance across the early stage portfolio has been generally resilient, which helps to validate the investment strategy that your Company has been following for a number of years. The Board and the Manager recognise the importance of regular tax free Shareholder distributions and an interim dividend of 1.00p per share has been declared for payment in December 2023.

 

Whilst the outlook for the UK economy has improved slightly, during the reporting period inflation remained stubbornly high and interest rates continued to rise, which created a challenging operating environment for many businesses and consumers. Notwithstanding the market conditions, your Company has delivered a robust performance. This reflects the strength of the underlying portfolio that has been carefully constructed over recent years and provides exposure to a wide range of high quality, growth companies, many of which operate in defensive or emerging sectors where demand has continued to grow. It is worthwhile noting that, across the portfolio, the level of external debt remains low, which provides a degree of insulation against further upward movements in interest rates and, furthermore, there is limited direct exposure to consumer facing sectors. The Board and the Manager believe that the underlying growth prospects for the majority of companies within the portfolio remain positive, and that your Company is well positioned to continue to progress its long term investment objective.

 

In May 2023, your Company closed its most recent Offer for Subscription, raising a total of £6.74 million for the 2022/23 and 2023/24 tax years. This new capital provides additional liquidity to support the further expansion and development of the portfolio through the completion of new investments and the provision of follow-on funding to support those companies that are achieving their commercial targets and require additional capital to fully scale before progressing towards an exit. During the period, two new private companies were added to the portfolio, both of which provide disruptive software solutions and operate in growing end markets. Maven remains focused on identifying companies that can demonstrate meaningful commercial traction and the potential for further strong revenue growth. This is often measured in terms of contracted annual recurring revenues (ARR), which provides a degree of visibility on a company's growth trajectory. Maven's regional network of investment executives continues to review a healthy pipeline of opportunities and, at the time of writing, there are several potential investments, across a wide range of sectors, which are at various stages of due diligence and legal contract. Based on this pipeline, it is anticipated that new investments will be completed during the second half of this financial year.

 

Your Company continues to follow a strategy focused on constructing a large and sectorally diversified portfolio of dynamic and entrepreneurial private and AIM quoted companies that operate in attractive markets such as Software-as-a-Service (SaaS), cyber security, data analytics and healthcare, where growth is less dependent on the conditions in the wider economy. Most companies within the unlisted portfolio have continued to make positive progress, with some of the more mature holdings now trading ahead of pre-pandemic levels. In the earlier stage portfolio, most companies are meeting their commercial milestones, increasing ARR and achieving further scale. Where there has been sustained positive performance, valuations have been uplifted, although the impact has been moderated by the well-publicised reduction in valuation multiples across public and private markets, particularly within the technology sector.

 

The performance of the AIM portfolio has continued to be muted. Although some listed markets have experienced a recovery, investor sentiment towards AIM continues to be subdued and there has been limited IPO and new share issuance activity to help stimulate demand. As a result of these market conditions, the overall value of your Company's AIM portfolio has declined. For the majority of holdings, the share price reductions reflect the general market volatility that has persisted throughout the period as well as the reduced appetite for investment in smaller, earlier stage growth businesses. The Board and the Manager nevertheless believe that, over the long term, selective exposure to AIM offers the potential to broaden the portfolio, as well as providing the ability to generate early liquidity if companies perform well. During the reporting period, a small position was taken in one new AIM quoted company that operates in the growth area of personalised healthcare. The Manager will, however, remain highly selective on any further AIM investments until there is clear evidence of a recovery in this market, and an improvement in the quality and quantity of companies seeking VCT funding.

 

The Manager maintains an active approach to portfolio management, with a view to supporting investee companies throughout the period of ownership. The Maven appointed board representative works closely with each unlisted portfolio company that is considering, or is engaged in, a sale process, helping to identify the most suitable corporate finance adviser and potential acquirers that may be willing to pay a premium or strategic price for the business. Whilst there have been no material realisations during the period, there remains a good level of external interest in several portfolio companies and, based on historical trends, the Manager is optimistic that M&A activity will resume when economic conditions stabilise.

 

Liquidity Management

 

As Shareholders will be aware from recent Annual and Interim Reports, your Company has a proactive approach to liquidity management, with the objective of generating income from cash resources held prior to investment in VCT qualifying companies. This strategy also helps to satisfy the criteria of the Nature of Income condition, which is a mandatory requirement of the VCT legislation. Not less than 70% of a VCT's income must be derived from shares or securities and, in order to meet this requirement, the Board had previously approved the construction of a focused portfolio of permitted, non-qualifying holdings in carefully selected investment trusts with strong fundamentals and attractive income characteristics. The recent upward trend in interest rates has, however, required the Board and the Manager to revise this approach. Following a whole of market review, the Manager has constructed a portfolio of leading money market funds and investment trusts that will allow your Company to maximise the income receivable on residual cash, whilst also ensuring compliance with the Nature of Income condition. During the reporting period, several new investments were completed in support of the revised liquidity management strategy, details of which can be found in the Investments table in the Interim Report.

 

Interim Dividend

 

In respect of the year ending 29 February 2024, an interim dividend of 1.00p per share will be paid on 1 December 2023 to Shareholders who are on the register at 3 November 2023. Since the Company's launch, and after receipt of this interim dividend, a total of 106.41p per share will have been paid in tax free Shareholder distributions. It should be noted that payment of a dividend reduces the NAV of the Company by the total cost of the distribution.

 

Dividend Policy

 

Decisions on distributions take into consideration a number of factors, including the realisation of capital gains, the adequacy of distributable reserves, the availability of surplus revenue and the VCT qualifying level, all of which are kept under close and regular review. The Board and the Manager recognise the importance of tax free distributions to Shareholders and, as a guide and subject to the considerations outlined above, will seek to pay an annual dividend that represents 5% of the NAV per share at the immediately preceding year end.

 

As the portfolio continues to expand and a greater proportion of holdings are in younger companies with growth potential, the timing of distributions will be more closely linked to realisation activity, whilst also reflecting the Company's requirement to maintain its VCT qualifying level. If larger distributions are required as a consequence of significant exits, this will result in a corresponding reduction in NAV per share. However, the Board and the Manager consider this to be a tax efficient means of returning value to Shareholders.

 

Dividend Investment Scheme (DIS)

 

Your Company operates a DIS, through which Shareholders can, at any time, elect to have their dividend payments utilised to subscribe for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax relief applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances.

 

In order for the DIS to apply in respect of the interim dividend that is due to be paid on 1 December 2023, a mandate form must be received by the Registrar (The City Partnership) before 17 November 2023, this being the relevant dividend election date, and that election will apply in respect of all future dividends until the Registrar is instructed to the contrary. The mandate form, terms & conditions and full details of the scheme (including tax considerations) are available from the Company's webpage at: mavencp.com/migvct. Election to participate in the DIS can also be made through the Registrar's online investor hub at: maven-cp.cityhub.uk.com/login.

 

If a Shareholder is in any doubt about the merits of participating in the DIS, or their own tax status, they should seek advice from a suitably qualified adviser.

 

Offers for Subscription

 

On 7 October 2022, your Company, alongside the other three Maven managed VCTs, launched Offers for Subscription. The Offers closed on 26 May 2023 with your Company raising a total of £6.74 million for the 2022/23 and 2023/24 tax years.

 

With respect to the 2022/23 tax year, an allotment of 8,130,478 new Ordinary Shares completed on 3 March 2023, with a further allotment of 4,986,813 new Ordinary Shares on 5 April 2023. An allotment of 2,013,349 new Ordinary Shares for the 2023/24 tax year took place on 2 June 2023.

 

The Directors are confident that Maven's regional office network will continue to source and complete investments in VCT qualifying companies across a range of sectors, and that the additional liquidity provided by the fundraising will facilitate further expansion and development of the portfolio in line with the investment strategy. Furthermore, the funds raised will allow your Company to maintain its share buy-back policy, whilst also spreading costs over a wider asset base in line with the objective of maintaining a competitive total expense ratio for the benefit of all Shareholders.

 

As announced on 13 October 2023, the Company launched a new Offer for Subscription alongside the three other Maven managed VCTs. Your Company has a target raise of £5 million, with the ability to utilise an over- allotment facility for up to a further £2.5 million. The Prospectus can be found at: mavencp.com/vctoffer.

 

Portfolio Developments

 

Graduate recruitment specialist Bright Network continues to make positive progress, with revenues now in excess of £11 million and over 900,000 active members. Working with over 300 partner firms such as Amazon, Bloomberg, Google and Vodafone, Bright Network offers a comprehensive range of services, including advice and support to assist its members in securing their first job or internship, as well as access to a range of in-person networking events. The business is committed to serving a diverse range of applicants and it is encouraging to note that 79% of its members are state educated, 55% are female and 40% are from first generation university households. During 2021, the business launched its Technology Academy, which seeks to address the digital skills shortage by providing high performing graduates with an intensive software development training programme, and then deploying them in client organisations. Over the past year, the Technology Academy has made good progress and already has consultants deployed with Lloyds Bank and Marks & Spencer. It was also named the Learning Solution of the Year at the 2022 Tiara Talent Tech Star Awards, which recognise excellence in the recruitment and talent acquisition industry. During the period, follow-on funding was provided to support the targeted international expansion strategy, which has achieved a successful launch in Germany.

 

Following a challenging period during the pandemic, when global electronic component shortages and supply chain disruption impacted order fulfilment capabilities, specialist manufacturer CB Technology has experienced a good recovery, with sales now back to pre-pandemic levels. Over recent years, the strategy to diversify the customer base away from a reliance on the oil & gas sector has been successful, with new clients secured in sectors such as communication, instrumentation and medical technology, where demand has remained resilient. To support future growth, the business continues to make strategic investments to ensure that it has the necessary infrastructure in place to best serve its clients. As part of this initiative, it is implementing a new enterprise resource planning (ERP) system, which will help to improve operational efficiency. With a strong orderbook, the outlook for the year ahead is positive.

 

Over recent years, cybercrime has become an increasing threat to everyday business activities, with most companies and organisations recognising the need to implement robust defences. Against this backdrop, cyber security specialist CYSIAM has made good commercial progress. The business provides a 24/7 managed detection and response service that aims to reduce system security breaches and stop ransomware attacks. It is also a preferred partner to public sector organisations in the UK. The CYSIAM team are experts in their field, with backgrounds in military intelligence, law enforcement and national security, which has enabled the business to launch a consultancy arm that is making positive progress. Its consultants work with clients to help them understand their security position and to build appropriate cyber resilience. CYSIAM has achieved good growth during the year to date, and the outlook is encouraging.

 

Following changes to the senior leadership team and the appointment of a new CEO, data transfer specialist DiffusionData has delivered strong growth, with ARR nearly doubling since your Company first invested in 2020. The business, which provides a market leading platform to improve the speed, security and efficiency of critical data transfer, is focused on the financial services, gaming and internet of things (IoT) markets, where accurate and timely data transfer is vital. DiffusionData has established a blue chip client base that includes 188 Bet, Baker Technology, Betfair, Caesars, Lloyds Bank and William Hill. To support the growth strategy, a new engineering and testing hub is being established in Newcastle, which will serve as a quality and assurance centre to ensure that DiffusionData can maintain its high standard of service delivery. In 2022, the business achieved notable industry recognition for its innovative data platform, winning four awards and being shortlisted for a further twelve.

 

During the period under review, sustainable packaging manufacturer iPac Packaging Innovations has continued to deliver a good rate of sales growth and has a strong pipeline of new opportunities. The business manufactures and supplies thermoformed sustainable packaging solutions to the food and pharmaceutical sectors, and recently opened its sixth production line to accommodate increased demand. In February 2023, it opened a new production and warehousing facility in County Durham, which has capacity to house up to eight new production lines that will be phased in to meet client demand. iPac continues to develop new products and its strategic objective is to move into adjacent markets where there is demand for sustainable packaging solutions. Given its strong and expanding product portfolio, coupled with attractive ESG credentials, the business is well placed to continue to deliver further growth in the year ahead.

 

Crematorium developer and operator Horizon Ceremonies continues to make good operational and strategic progress. Since your Company first invested in 2017, it has established a portfolio of three crematoria, all of which are trading ahead of plan, and the business is continuing to build a strong market position. Whilst the planning process for a new crematorium can be lengthy, there is a good pipeline of opportunities at varying stages of the approval process. The medium term strategic objective remains to build a portfolio of modern, technologically advanced crematoria that offer a professional and compassionate service whilst also meeting the highest environmental standards, and to sell the business to a trade, private equity or infrastructure acquirer when all of the sites are fully developed.

 

Liftango, a provider of an environmentally friendly transport planning solution, has achieved significant sales growth since your Company first invested in December 2021. The business enables corporates, universities and public transport providers, to plan, launch and scale sustainable transport solutions, including climate-positive carpooling, fixed-route shuttles and on-demand buses, and recently signed a five year contract with National Express to digitalise its existing dial-a-ride service, adding another client to an impressive blue chip list that includes Amazon, IKEA, Qantas, Tesla and Volvo. The near term objective remains to accelerate international growth and capitalise on emerging opportunities in Europe and North America, whilst also broadening the product offering to existing customers and regions.

 

Digital archiving specialist MirrorWeb continues to deliver impressive revenue growth. Having established the business in the UK, MirrorWeb is now focused on expansion into the US, which is viewed as a pivotal market. The international growth strategy is being led by the CEO, who relocated to Texas earlier this year. The immediate focus is to increase sales by targeting large financial institutions and compliance consultancies, where the need to archive digital communications is either a regulatory or best practice requirement, and where MirrorWeb's comprehensive product offering provides a compelling solution. The business will also continue to build its presence in the UK, where its blue chip customer base includes Aegon, Baillie Gifford, the BBC, HM Treasury, Tesco Bank and The National Archives.

 

During the period under review, Rockar, a developer of a disruptive digital platform for buying new and used cars, has made positive progress and further enhanced its position in the evolving automotive eCommerce market. The business provides a white label cloud-based solution to help manufacturers and retailers develop digital alternatives to replace or complement existing showroom models and has recently added Volvo to a client base that includes BMW, Jaguar Land Rover, Porsche and Toyota. The strategy for the year ahead remains focused on building relationships with global automotive manufacturers to enable the business to scale further.

 

Whilst the majority of companies in the unlisted portfolio have continued to make positive progress, there are a small number that have not achieved their commercial targets, largely as a result of conditions within the wider economy. In specific cases, valuations have been reduced to reflect the lower than expected trading performance and, consistent with Maven's proactive approach to portfolio management, the Manager has been instrumental in helping management teams to identify the specific issues facing their business and implementing measures to help them return to growth.

 

New Investments

 

During the reporting period, two new private companies were added to the portfolio:

 

? iAM Compliant is a software business that has established a strong position in the eLearning market and has two distinct divisions that operate independently. iAM Compliant is a cloud-based estates and compliance management platform, covering areas such as estates management, health and safety, status reporting and premises checks. The business has achieved a good rate of recurring revenue and maintains a high client retention rate. iAM Learning has developed a digital learning library that contains over 275 continuing professional development (CPD) and Institute of Occupational Safety and Health (IOSH) approved courses, covering a wide range of topics such as cyber security, leadership, mental health and safeguarding. The courses are designed to be accessible and engaging, and existing clients include Countrywide, DPD, Dunelm, Lotus Cars and Moonpig. The funding from the Maven VCTs will enable the business to enhance product development, support sales and marketing initiatives, and provide general working capital headroom.

 

? Manufacture 2030 (M2030) has developed a software solution to assist large corporates with complex manufacturing supply chains to work with their suppliers to measure and reduce carbon emissions. The platform enables companies to collate environmental impact data and formulate reduction strategies, before tracking progress and reporting this to their customers. M2030 has developed a strong client base, including multinationals such as Asda, Bayer, Ford, General Motors, Morrisons and SC Johnson. The funding from the Maven VCTs is being used to expand in key sectors such as automotive, chemical, pharmaceuticals and retail, and to support further product development to enhance the platform's functionality.

 

In addition, a small position was taken in AIM quoted biotechnology specialist Oxford BioDynamics, which is developing precision medicine tests for personalised healthcare. Your Company participated in the £5.6 million fundraising, with the VCT investment being used to provide working capital to support the development and commercialisation of the company's proprietary technology. Shortly after the period end, Oxford BioDynamics released a positive update to the market, which resulted in a material increase in the share price. This created the opportunity to partially realise the holding at a price that was significantly ahead of the entry level.

 

The table below gives details of the investments that were completed during the reporting period:

 

 

 

Investments

 

 

Date

 

 

Sector

Investment

cost

£'000

New unlisted

 

 

 

2 degrees Limited

(trading as Manufacture 2030)

March 2023

Software & technology

698

iAM Compliant Limited

May 2023

Learning & development/ recruitment technology

149

Total new unlisted

 

 

847

 

Follow-on unlisted

 

 

 

Bright Network (UK) Limited

July 2023

Learning & development/ recruitment technology

224

Draper & Dash Limited

(trading as RwHealth)

April 2023

Pharmaceuticals, biotechnology & healthcare

75

Enpal Limited (trading as Guru Systems)

April 2023

Software & technology

191

Hublsoft Group Limited

August 2023

Software & technology

55

Shortbite Limited (trading as Fixtuur)

July 2023

Software & technology

100

Turnkey Group (UK) Holdings Limited1

March & August 2023

Software & technology

421

Zinc Digital Business Solutions Limited1

April & June 2023

Software & technology

104

Total follow-on unlisted

 

 

1,170

 

 

 

 

Total unlisted

 

 

2,017

 

New AIM quoted

 

 

 

Oxford BioDynamics PLC

August 2023

Pharmaceuticals, biotechnology & healthcare

99

Total new AIM quoted

 

 

99

 

 

 

 

Total AIM quoted

 

 

99

 

Open-ended investment companies2

 

 

 

Royal London Short Term Fixed Income Fund (Class Y Income)

June 2023

Money market fund

9

Royal London Short Term Money Market Fund (Class Y Income)

June 2023

Money market fund

36

Total open-ended investment companies

 

 

45

 

Investments

Date

Sector

Investment

cost

£'000

Money market funds2

 

 

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

May 2023

Money market fund

1,011

Aviva Investors Sterling Government Liquidity Fund

August 2023

Money market fund

1,000

Aviva Investors Sterling Liquidity Fund (Class 3)

June 2023

Money market fund

1,007

BlackRock Institutional Sterling Government Liquidity Fund (Core Dis)

August 2023

Money market fund

1,000

BlackRock Institutional Sterling Liquidity Fund (Core)

June 2023

Money market fund

1,007

Goldman Sachs Sterling Government Liquid Reserves Ireland (Institutional)

June 2023

Money market fund

1,007

Total money market funds

 

 

6,032

 

Private equity investment trusts2

 

 

 

abrdn Private Equity Opportunities Trust PLC (formerly Standard Life Private Equity Trust PLC)

March 2023

Investment trust

151

Alliance Trust PLC

May 2023

Investment trust

80

Apax Global Alpha Limited

May 2023

Investment trust

50

HgCapital Trust PLC

March 2023

Investment trust

400

ICG Enterprise Trust PLC

June 2023

Investment trust

176

NB Private Equity Partners Limited

March 2023

Investment trust

329

Total private equity investment trusts

 

 

1,186

 

Real estate investment trust2

 

 

 

Impact Healthcare REIT PLC

June 2023

Investment trust

114

Total real estate investment trust

 

 

114

 

Infrastructure investment trusts2

 

 

 

3i Infrastructure PLC

May 2023

Investment trust

150

BBGI Global Infrastructure SA

May 2023

Investment trust

140

International Public Partnerships Limited

May 2023

Investment trust

140

JLEN Environmental Assets Group Limited

May 2023

Investment trust

150

Pantheon Infrastructure PLC

May 2023

Investment trust

140

Total infrastructure investment trusts

 

 

720

 

 

 

 

Total investments

 

 

10,213

 

1 Follow-on investment completed in two tranches.

2 Investments completed as part of the liquidity management strategy, details of which can be found in the Interim Report.

 

At the period end, the portfolio comprised of 121 unlisted and quoted investments, at a total cost of £49.41 million.

 

Realisations

 

The table below gives details of the realisations completed during the reporting period:

 

Realisations

Year first

invested

 

Complete/

partial

exit

Cost of shares disposed of

£'000

Value at

28 February

2023

£'000

Sales proceeds

£'000

Realised

gain/ (loss)

£'000

Gain/(loss)

over

28 February 2023 value

£'000

Unlisted

 

 

 

 

 

 

 

ADC Biotechnology Limited1

2017

Complete

-

-

129

129

129

Cardinality Limited2

2021

Complete

-

-

20

20

20

Ensco 969 Limited (trading as DPP)3

2013

Partial

63

74

63

-

(11)

Maven Co-invest Endeavour Limited Partnership4

2013

Complete

2

539

556

554

17

R&M Engineering Group Limited

2013

Complete

762

172

120

(642)

(52)

Total unlisted

 

 

827

785

888

61

103

 

Money market funds

 

 

 

 

 

 

 

Aviva Investors Sterling Liquidity Fund (Class 3)

2023

Complete

1,007

1,007

1,007

-

-

BlackRock Institutional Sterling Liquidity Fund (Core)

2023

Complete

1,007

1,007

1,007

-

-

Total money market funds

 

 

2,014

2,014

2,014

-

-

 

 

 

 

 

 

 

 

Total realisations

 

 

2,841

2,799

2,902

61

103

 

1 Deferred consideration following the sale in March 2021.

2 Deferred consideration following the sale in August 2022.

3 Proceeds from loan note repayment exclude yield received, which is disclosed as revenue for financial reporting purposes.

4 Release of monies following the sale of the underlying company in June 2022.

 

Material Developments Since the Period End

 

Since 31 August 2023, two new private company holding(s) has/have been added to the portfolio:

 

Drovo is a marketing technology business that specialises in on-vehicle advertising. The business has developed a platform that uses digital roof-top screens alongside an integrated software application to give companies and marketing agencies superior insight into the effectiveness of advertising reach. Its technology goes beyond traditional advertising, as the digital screens can be adapted in real time, allowing products to be advertised based on the location of the vehicle or potential customers. The funding by the Maven VCTs is being used to enable the digital screen business to expand and take advantage of a market opportunity, whilst also providing working capital to support the business as it grows.

 

Laverock Therapeutics is a specialist pre-clinical drug discovery company that has developed a gene silencing platform for use in the creation of next generation cell therapies focusing on diabetes, solid tumour immunotherapy and T-Cells. Its differentiated technology enables the development of cell therapies that are stable and programmable, which offers scope to improve the efficacy and safety, whilst also addressing many of the limitations of existing approaches. The funding from the Maven VCTs is being used to validate the core technology and generate pre-clinical data across key programmes.

 

Principal and Emerging Risks and Uncertainties

 

The principal and emerging risks and uncertainties facing the Company were set out in full in the Strategic Report contained within the 2023 Annual Report, and are the risks associated with investment in small and medium sized unlisted and AIM/AQSE quoted companies which, by their nature, carry a higher level of risk and are subject to lower liquidity than investments in larger quoted companies. The valuation of investee companies may be affected by economic conditions, the credit environment and other risks such as legislation, regulation, adherence to VCT qualifying rules and the effectiveness of the internal controls operated by the Company and the Manager. These risks and procedures are reviewed regularly by the Risk Committee and reported to your Board. The Board has confirmed that all tests, including the criteria for VCT qualifying status, continue to be monitored and met.

 

The invasion of Ukraine by Russia was added to the Risk Register as an emerging risk during a previous period, as the Directors were not only aware of the heightened cyber security risk but were mindful of the impact that any change in the underlying economic conditions could have on the valuation of investee companies. These included fluctuating interest rates, increased fuel and energy costs, and the availability of bank finance, all of which could be impacted during times of geopolitical uncertainty and volatile markets. The Board and the Manager continue to monitor the impact of the conflict, and wider market conditions, on portfolio companies.

 

Share Buy-backs

 

Shareholders will be aware that a primary objective for the Board is to ensure that the Company retains sufficient liquidity for making investments in line with its stated policy, and for the continued payment of dividends. However, the Directors also acknowledge the need to maintain an orderly market in the Company's shares and have, therefore, delegated authority to the Manager for the Company to buy back shares in the market, for cancellation or to be held in treasury, subject always to such transactions being in the best interests of Shareholders.

 

It is intended that, subject to market conditions, availability liquidity and the maintenance of the Company's VCT qualifying status, the Company should seek to maintain a share price that is at approximately a 5% discount to the latest published NAV per share.

 

Shareholders should be aware that neither the Company nor the Manager can execute a direct transaction in the Company's shares. Any instruction to buy or sell shares on the secondary market must be directed through a stockbroker. If a Shareholder wishes to buy or sell shares on the secondary market, they or their broker can contact the Company's corporate broker, Shore Capital Stockbrokers on 020 7647 8132, to discuss a transaction. It should, however, be noted that such transactions cannot take place whilst the Company is in a closed period, which is the time from the end of a reporting period (quarter end, half year or full year) until the announcement of the relevant results, or the release of an unaudited NAV. A closed period may also be introduced if the Directors and Manager are in possession of price sensitive information which may further restrict the Company's ability to buy back shares.

 

During the period under review, 984,000 shares were bought back at a total cost of £390,000.

 

VCT Regulatory Update

 

During the period under review, there were no further amendments to the rules governing VCTs. However, Shareholders may be aware that, as approved by the European Commission in 2015, the VCT scheme included a "sunset clause", which provided that, unless the legislation was renewed by an HM Treasury order, income tax relief would no longer be available on subscriptions for new shares in VCTs made on or after 6 April 2025. There has been a considerable level of activity by industry representatives such as the Venture Capital Trust Association (VCTA), of which the Manager is an active member, and The Association of Investment Companies (AIC), of which the Company is a member, to demonstrate the important role of VCT investment in supporting SMEs across the country and stimulating economic growth and regional employment. The Board and the Manager welcomed the announcement by the UK Government in its Autumn 2022 budget statement of an intention to extend the income tax relief available on new VCT shares beyond 2025. This commitment was reaffirmed in the Spring 2023 budget and in the Chancellor's Mansion House speech on 10 July 2023. Through the VCTA the Manager will remain involved in discussions regarding the process for implementing this extension.

 

Consistent with industry best practice, the Board and the Manager continue to apply the International Private Equity and Venture Capital Valuation (IPEV) Guidelines (Valuation Guidelines) as the central methodology for all private company valuations. The Valuation Guidelines are the prevailing framework for fair value information in the private equity and venture capital industry, and the Directors and the Manager continue to adhere to the Valuation Guidelines when assessing all private company investments.

 

The Consumer Duty

 

In July 2023, the FCA's new Consumer Duty came into effect. This requires firms that are subject to the new Consumer Duty rules to ensure that they are acting to deliver good retail consumer outcomes and that their strategies, governance, leadership and policies reflect this. Although the Consumer Duty does not apply directly to the Company, the Manager, as an FCA authorised firm, is within its scope and is providing the Directors with regular updates on the work that has been undertaken to ensure that good outcomes are being delivered for Shareholders.

 

Environmental, Social and Governance (ESG) Considerations

 

Whilst your Company's investment policy does not incorporate specific ESG objectives, and investee companies are not required to meet any particular targets, Maven continues to develop its ESG framework and oversight capabilities, recognising the benefits and importance of incorporating these core principles into its investment approach. Early stage ESG due diligence is now a standard part of the pre-investment decision making process and is a core component within the selection criteria, thereby ensuring that all ESG risks and opportunities are discussed fully prior to the completion of any investment. During the period under review, in recognition of the growth within this area and the requirement to record and monitor detailed ESG information across the portfolio, the Manager has invested additional resource into its ESG capabilities.

 

The ESG regulatory landscape is evolving constantly, and the Manager provides the Board with regular updates on the latest developments. A relevant regulation is the Task Force on Climate-related Financial Disclosures (TCFD), on which neither the Company nor the Manager are required to report. However, the Board and the Manager acknowledge the aims and importance of the TCFD and, therefore, reporting in line with TCFD is an objective of the Manager as part of its approach to ESG.

 

Your Company has multiple investments in companies with strong ESG credentials that are achieving growth in their markets, and the Manager is committed to maintaining a responsible approach to new and existing investments. The Manager continues to be an active signatory to the UN Principles for Responsible Investment (UNPRI) and recently submitted its first UNPRI report to demonstrate its ESG capabilities and commitment to the Principles. Additionally, the Manager is a signatory to the Investing in Women Code, which aims to reduce barriers to tools, resources and finance for UK based female entrepreneurs.

 

Outlook

 

With good levels of liquidity, your Company's strategy remains focused on further growing and developing the investee company portfolio. After a quiet first half of the year, the pipeline of potential new investments across Maven's regional network of offices has improved and it is anticipated that there will be a higher rate of new private company investment activity during the second half of the year. The Manager will also continue to work closely with existing portfolio companies, particularly those that are growing rapidly and demonstrating the potential to create significant Shareholder value, to ensure that their value is maximised at the point of exit. This dual focus on portfolio expansion and value maximisation is aimed at ensuring that a steady flow of profitable exits occur, in support of the objective of providing Shareholders with regular tax free dividend payments.

 

On behalf of the Board

Maven Capital Partners UK LLP

Secretary

 

18 October 2023

 

 

Summary of Investment Changes

 

For the Six Months Ended 31 August 2023

 

 

Valuation

28 February 2023

Net investment/ (disinvestment)

£'000

Appreciation/ (depreciation)

£'000

Valuation

31 August 2023

£'000

%

£'000

%

Unlisted investments

 

 

 

 

 

 

Equities

33,197

57.6

1,215

(1,150)

33,262

54.8

Loan stock

8,068

14.0

211

(76)

8,203

13.5

 

41,265

71.6

1,426

(1,226)

41,465

68.3

AIM/AQSE investments1

 

 

 

 

 

 

Equities

1,804

3.1

(128)

39

1,715

2.8

 

Listed investments2

 

 

 

 

 

 

Investment trusts

1,279

2.2

2,020

(47)

3,252

5.3

OEICs

3,005

5.2

45

14

3,064

5.0

Money market funds

-

-

4,018

-

4,018

6.6

Total investments

47,353

82.1

7,381

(1,220)

53,514

88.0

 

Net current assets

 

10,287

 

17.9

 

(3,093)

 

-

 

7,194

 

12.0

Net assets

57,640

100.0

4,288

(1,220)

60,708

100.0

 

1 Shares traded on the Alternative Investment Market (AIM) and the Aquis Stock Exchange (AQSE).

2 These holdings represent the liquidity management portfolio, which has been constructed from a range of carefully selected, permitted non-qualifying holdings in open-ended investment companies (OEICs), investment trusts and money market funds.

 

 

Investment Portfolio Summary

 

As at 31 August 2023

 

Investment

Valuation £'000

Cost £'000

% of total assets

% of equity held

% of equity held by other clients1

Unlisted

 

Bright Network (UK) Limited

2,403

1,164

4.1

7.5

35.2

DiffusionData Limited (formerly Push Technology Limited)2

1,681

875

2.9

3.8

12.7

Horizon Ceremonies Limited (trading as Horizon Cremation)

1,535

788

2.5

4.2

48.5

MirrorWeb Limited

1,503

890

2.5

6.3

43.6

Rockar 2016 Limited (trading as Rockar)

1,404

948

2.3

4.2

15.3

Horizon Technologies Consultants Limited

1,326

796

2.2

5.5

11.7

NorthRow Limited (formerly Contego Solutions Limited)

1,179

1,179

1.9

6.5

25.7

GradTouch Limited

1,133

567

1.9

5.3

29.3

Nano Interactive Group Limited

1,126

625

1.9

3.7

11.2

Martel Instruments Holdings Limited

1,058

807

1.7

14.9

29.3

BioAscent Discovery Limited

1,056

174

1.7

4.4

35.6

Delio Limited

1,046

782

1.7

3.1

10.5

Precursive Limited

1,000

1,000

1.6

6.7

27.5

Relative Insight Limited

953

700

1.6

3.0

28.7

CB Technology Group Limited

951

579

1.6

11.2

63.8

mypura.com Group Limited (trading as Pura)

896

448

1.5

2.3

20.1

Enpal Limited (trading as Guru Systems)

888

888

1.5

7.5

14.1

Ensco 969 Limited (trading as DPP)

869

633

1.4

4.9

29.6

Vodat Communications Group Limited

852

567

1.4

5.0

26.9

Bud Systems Limited

846

846

1.4

4.8

12.2

HCS Control Systems Group Limited

843

846

1.4

6.9

29.6

Hublsoft Group Limited

812

730

1.3

5.5

18.3

XR Games Limited

805

497

1.3

2.8

17.4

Zinc Digital Business Solutions Limited

801

801

1.3

10.9

23.7

Rico Developments Limited (trading as Adimo)

760

760

1.3

3.3

6.4

Novatus Global Limited

746

746

1.2

5.0

8.3

2 Degrees Limited (trading as Manufacture 2030)

698

698

1.1

2.5

8.6

QikServe Limited

659

659

1.1

3.0

12.8

CYSIAM Limited

630

373

1.0

6.5

13.5

Cat Tech International Limited

623

627

1.0

6.0

24.0

Turnkey Group (UK) Holdings Limited

620

620

1.0

8.3

30.4

Liftango Group Limited

598

598

1.0

2.5

11.5

Whiterock Group Limited

561

321

0.9

5.2

24.8

Glacier Energy Services Holdings Limited

544

688

0.9

2.7

25.0

WaterBear Education Limited

517

245

0.9

5.1

34.1

ORCHA Health Limited

497

497

0.8

1.2

7.5

Plyable Limited

497

497

0.8

4.7

12.7

Reed Thermoformed Packaging Limited (trading as iPac Packaging Innovations)

477

448

0.8

2.5

9.9

Biorelate Limited

468

468

0.8

2.7

23.1

CODILINK UK Limited (trading as Coniq)

450

450

0.7

1.3

3.6

Summize Limited

448

448

0.7

2.9

30.2

Filtered Technologies Limited

435

400

0.7

4.1

21.3

ebb3 Limited

423

252

0.7

8.0

70.9

Flow UK Holdings Limited

420

598

0.7

7.3

27.7

Shortbite Limited (trading as Fixtuur)

390

584

0.6

7.5

67.4

Draper & Dash Limited (trading as RwHealth)

373

373

0.6

1.5

12.1

HiveHR Limited

346

346

0.6

4.4

40.2

Boomerang Commerce Inc (trading as CommerceIQ)3

338

451

0.6

0.1

0.4

Growth Capital Ventures Limited

300

288

0.5

5.3

42.1

FodaBox Limited

299

299

0.5

1.0

4.0

Snappy Shopper Limited

298

298

0.5

0.4

1.3

TC Communications Holdings Limited

241

413

0.4

3.5

26.5

Automated Analytics Limited (formerly eSales Hub Limited)

150

150

0.2

1.9

18.7

iAM Compliant Limited

149

149

0.2

1.9

36.9

The Algorithm People Limited (trading as Optimize)

140

140

0.2

2.0

14.2

ISN Solutions Group Limited

127

323

0.2

4.6

50.4

Project Falcon Topco Limited (trading as Quorum Cyber)4

126

126

0.2

0.3

2.6

RevLifter Limited

100

100

0.2

1.0

25.6

LightwaveRF PLC5

40

74

0.1

0.9

0.9

Other unlisted investments

11

1,380

-

 -

 -

Total unlisted

41,465

34,017

68.3

 

Investment

Valuation £'000

Cost £'000

% of total assets

% of equity held

% of equity held by other clients1

AIM/AQSE quoted

 

Kanabo Group PLC6

227

1,639

0.5

2.1

7.9

GENinCode PLC

205

397

0.4

1.8

9.3

Arecor Therapeutics PLC

137

167

0.3

0.2

0.2

Intelligent Ultrasound Group PLC

135

118

0.2

0.4

1.5

Destiny Pharma PLC

122

150

0.2

0.2

0.9

Oxford BioDynamics PLC

97

99

0.2

0.4

1.3

Avacta Group PLC

90

13

0.1

 -

0.1

SulNOx PLC

70

130

0.1

0.4

0.4

Polarean Imaging PLC

60

246

0.1

0.2

0.4

Eden Research PLC

56

59

0.1

0.2

1.0

C4X Discovery Holdings PLC

48

40

0.1

0.1

0.8

Feedback PLC

45

74

0.1

0.4

1.3

Crossword Cybersecurity PLC

43

150

0.1

0.6

1.5

LungLife AI

40

82

0.1

0.2

0.3

Saietta Group PLC

37

111

0.1

0.1

0.1

Directa Plus PLC

34

120

0.1

0.1

0.1

Oncimmune Holdings PLC

29

236

-

0.2

0.3

Velocys PLC

27

148

-

0.1

0.1

Incanthera PLC

25

49

-

0.6

0.6

Vianet Group PLC

22

37

-

0.1

1.3

RUA Life Sciences PLC

21

149

-

0.6

1.1

Verici Dx PLC

21

83

-

0.1

1.4

Gelion PLC

20

121

-

0.1

0.1

Strip Tinning PLC

20

62

-

0.2

-

ReNeutron Group PLC

18

136

-

0.3

1.8

Osirium Technologies PLC

15

198

-

0.6

1

Hardide PLC

14

80

-

0.2

0.3

Seeen PLC

13

148

-

0.4

0.6

XP Factory PLC

13

26

-

-

0.1

Other AIM/AQSE investments

11

282

-

-

-

Total AIM/AQSE quoted

1,715

5,350

2.8

 

Investment

Valuation £'000

Cost £'000

% of total assets

% of equity held

% of equity held by other clients1

Private equity investment trusts7

 

HgCapital Trust PLC

518

434

0.8

 -

0.1

abrdn Private Equity Opportunities Trust PLC (formerly Standard Life Private Equity Trust PLC)

380

349

0.6

0.1

0.2

ICG Enterprise Trust PLC

311

289

0.6

 -

0.1

NB Private Equity Partners Limited

306

329

0.5

 -

0.3

HarbourVest Global Private Equity Limited

302

194

0.5

 -

-

CT Private Equity Trust PLC (formerly BMO Private Equity Trust PLC)

212

135

0.3

0.1

0.2

Pantheon International PLC

139

107

0.2

0.1

0.2

Apax Global Alpha Limited

133

121

0.2

 -

0.1

Princess Private Equity Holding Limited

123

111

0.2

 -

0.1

Alliance Trust PLC

83

80

0.1

 -

-

Total private equity investment trusts

2,507

2,149

4.0

 

 

Real estate investment trust7

 

Impact Healthcare REIT PLC

106

114

0.2

-

-

Total real estate investment trust

106

114

0.2

Infrastructure investment trusts7

 

3i Infrastructure PLC

142

150

0.3

-

-

BBGI Global Infrastructure SA

130

140

0.2

-

-

International Public Partnerships Limited

128

140

0.2

-

-

JLEN Environmental Assets Group Limited

122

150

0.2

-

-

Pantheon Infrastructure PLC

117

140

0.2

-

0.1

Total infrastructure investment trusts

639

720

1.1

Open-ended investment companies7

 

Royal London Short Term Money Market Fund (Class Y Income)

2,050

2,036

3.4

-

0.1

Royal London Short Term Fixed Income Fund (Class Y Income)

1,014

1,009

1.6

-

-

Total open-ended investment companies

3,064

3,045

5.0

Money market funds7

 

Aberdeen Standard Liquidity Fund (Lux) - Sterling Fund (Class K3)

1,011

1,011

1.7

-

-

Goldman Sachs Sterling Government Liquid Reserves Ireland (Institutional)

1,007

1,007

1.7

0.4

0.8

Aviva Investors Sterling Government Liquidity Fund

1,000

1,000

1.6

-

-

BlackRock Institutional Sterling Government Liquidity Fund (Core Dis)

1,000

1,000

1.6

-

-

Total money market funds

4,018

4,018

6.6

Total investments

53,514

49,413

88.0

 

1 Other clients of Maven Capital Partners UK LLP.

2 John Pocock is executive chairman of this company.

3 This holding reflects the retained minority interest following the sale of e.fundamentals (Group) Limited to CommerceIQ in July 2022.

4 Retained minority interest following the sale of Quorum Cyber Security Limited in December 2022.

5 This company delisted from AIM during a previous period.

6 The holding in this investment resulted from the sale of The GP Service (UK) Limited, which completed in February 2022. During the reporting period, the unlisted shares in Kanabo GP Limited were, in accordance with the terms of the original transaction, exchanged for shares in AIM quoted Kanabo Group PLC.

7 Liquidity management portfolio.

 

Shaded line indicates that the investment was completed pre November 2015.

 

 

Income Statement

 

For the six months ended 31 August 2023

 

 

Six months ended

31 August 2023

(unaudited)

Six months ended

31 August 2022

(unaudited)

Year ended

28 February 2023

(audited)

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

(Losses)/gains on investments

-

(1,220)

(1,220)

-

60

60

-

2,449

2,449

Income from investments

380

-

380

325

-

325

587

-

587

Other income

106

-

106

11

-

11

91

-

91

Investment management fees

(120)

(482)

(602)

(121)

(486)

(607)

(238)

(952)

(1,190)

Other expenses

(261)

-

(261)

(225)

-

(225)

(545)

-

(545)

Net return on ordinary activities before taxation

105

(1,702)

(1,597)

(10)

(426)

(436)

(105)

1,497

1,392

 

Tax on ordinary activities

 

-

 

-

 

-

 

-

 

-

 

-

 

-

 

-

 

-

Return attributable to Equity Shareholders

105

(1,702)

(1,597)

(10)

(426)

(436)

(105)

1,497

1,392

 

Earnings per share (pence)

 

0.07

 

(1.16)

 

(1.09)

 

(0.01)

 

(0.32)

 

(0.33)

 

(0.08)

 

1.09

 

1.01

 

All gains and losses are recognised in the Income Statement.

 

The total column of this statement is the Profit & Loss Account of the Company. The revenue and capital columns are supplementary to this and are prepared under guidance published by the AIC. All items in the above statement are derived from continuing operations. The Company has only one class of business and one reportable segment, the results of which are set out in the Income Statement and Balance Sheet. The Company derives its income from investments made in shares, securities and bank deposits.

 

There are no potentially dilutive capital instruments in issue and, therefore, no diluted earnings per share figures are relevant. The basic and diluted earnings per share are, therefore, identical.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

 

Statement of Changes in Equity

 

For the Six Months Ended 31 August 2023

 

Six months ended

31 August 2023

(unaudited)

Non-distributable reserves

Distributable reserves

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 28 February 2023

13,400

15,714

569

6,767

(154)

20,785

559

57,640

Net return

-

-

-

(1,211)

(9)

(482)

105

(1,597)

Dividends paid

-

-

-

-

-

(1,713)

-

(1,713)

Repurchase and cancellation of shares

(98)

-

98

-

-

(389)

-

(389)

Net proceeds of share issue

1,513

5,092

-

-

-

-

-

6,605

Net proceeds of DIS issue1

39

123

-

-

-

-

-

162

At 31 August 2023

14,854

20,929

667

5,556

(163)

18,201

664

60,708

 

Six months ended

31 August 2022

(unaudited)

Non-distributable reserves

Distributable reserves

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve realised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 28 February 2022 (restated)2

13,532

15,496

370

4,910

(746)

25,777

664

60,003

Net return (restated)2

-

-

-

(1,059)

1,119

(486)

(10)

(436)

Dividends paid

-

-

-

-

-

(1,693)

-

(1,693)

Repurchase and cancellation of shares

(120)

-

120

-

-

(556)

-

(556)

Net proceeds of DIS issue1

35

118

-

-

-

-

-

153

At 31 August 2022 (restated)2

13,447

15,614

490

3,851

373

23,042

654

57,471

 

Year ended

28 February 2023

(audited)

Non-distributable reserves

Distributable reserves

 

 

 

Total

£'000

Share capital

£'000

Share premium account

£'000

Capital redemption reserve

£'000

Capital reserve realised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

At 28 February 2022

(restated)2

13,532

15,496

370

4,910

(746)

25,777

664

60,003

Net return

-

-

-

1,857

592

(952)

(105)

1,392

Dividends paid

-

-

-

-

-

(3,155)

-

(3,155)

Repurchase and cancellation of shares

(199)

-

199

-

-

(885)

-

(885)

Net proceeds of DIS issue1

67

218

-

-

-

-

-

285

At 28 February 2023

13,400

15,714

569

6,767

(154)

20,785

559

57,640

 

The capital reserve unrealised is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments that are distributable.

 

Where all, or an element of the proceeds of sales have not been received in cash or cash equivalent, and are not readily convertible to cash, they do not qualify as realised gains for the purposes of distributable reserves calculations and, therefore, do not form part of distributable reserves.

 

The accompanying Notes are an integral part of the Financial Statements.

 

1 DIS represents the Dividend Investment Scheme as detailed in the Investment Manager's Review.

2 The prior year net return split between capital reserve realised and capital reserve unrealised has been restated to reflect the element of gains recorded in the prior year that were not received in cash or cash equivalent, and were not readily convertible to cash and, therefore, did not qualify as realised gains for the purposes of distributable reserve calculations. The net impact is a movement of £904,360 from capital reserve realised to capital reserve unrealised. The adjustment had no impact on the balances at 28 February 2021.

 

 

 

Balance Sheet

 

As at 31 August 2023

 

 

 

31 August 2023 (unaudited)

£'000

31 August 2022 (unaudited) (restated)

£'000

28 February 2023

(audited)

£'000

Fixed assets

 

 

 

Investments at fair value through profit or loss

53,514

39,154

47,353

 

Current assets

 

 

 

Debtors

658

645

699

Cash

6,849

17,877

9,834

 

7,507

18,522

10,533

Creditors

 

 

 

Amounts falling due within one year

(313)

(205)

(246)

Net current assets

7,194

18,317

10,287

Net assets

60,708

57,471

57,640

 

Capital and reserves

 

 

 

Called up share capital

14,854

13,447

13,400

Share premium account

20,929

15,614

15,714

Capital redemption reserve

667

490

569

Capital reserve - unrealised

5,556

3,851

6,767

Capital reserve - realised

(163)

373

(154)

Special distributable reserve

18,201

23,042

20,785

Revenue reserve

664

654

559

Net assets attributable to Ordinary Shareholders

60,708

57,471

57,640

Net asset value per Ordinary Share (pence)

40.87

42.74

43.01

 

The Financial Statements of Maven Income and Growth VCT PLC, registered number 03908220, were approved and authorised for issue by the Board of Directors on 18 October 2023 and were signed on its behalf by:

 

 

 

 

John Pocock

Director

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

 

 

Cash Flow Statement

 

For the Six Months Ended 31 August 2023

 

 

Six months ended 31 August 2023 (unaudited)

£'000

Six months ended 31 August 2022 (unaudited)

£'000

Year ended

28 February 2023

(audited)

£'000

Net cash flows from operating activities

(339)

(515)

(1,083)

 

Cash flows from investing activities

 

 

 

Purchase of investments

(10,213)

(5,684)

(12,145)

Sale of investments

2,902

2,834

3,479

Net cash flows from investing activities

(7,311)

(2,850)

(8,666)

 

Cash flows from financing activities

 

 

 

Equity dividends paid

(1,713)

(1,693)

(3,155)

Issue of Ordinary Shares

6,605

-

-

Net proceeds of DIS issue

162

153

285

Repurchase of Ordinary Shares

(389)

(556)

(885)

Net cash flows from financing activities

4,665

(2,096)

(3,755)

 

 

 

Net decrease in cash

(2,985)

(5,461)

(13,504)

 

Cash at beginning of period

 

9,834

 

23,338

 

23,338

Cash at end of period

6,849

17,877

9,834

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Notes to the Financial Statements

 

For the Six Months Ended 31 August 2023

 

1 Accounting policies

 

The financial information for the six months ended 31 August 2023 and the six months ended 31 August 2022 comprises non-statutory accounts within the meaning of S435 of the Companies Act 2006.The financial information contained in this report has been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 28 February 2023, which have been filed at Companies House and contained an Auditor's Report that was not qualified and did not contain a statement under S498(2) or S498(3) of the Companies Act 2006.

 

2 Reserves

 

Share premium account

 

The share premium account represents the premium above nominal value received by the Company on issuing shares net of issue costs. This reserve is non-distributable.

 

Capital redemption reserve

 

The nominal value of shares repurchased and cancelled is represented in the capital redemption reserve. This reserve is non-distributable.

 

Capital reserve - unrealised

 

Increases and decreases in the fair value of investments are recognised in the Income Statement and are then transferred to the capital reserve unrealised account. This reserve is generally non-distributable other than the part of the reserve relating to gains/(losses) attributable to readily realisable quoted investments that are distributable.

 

Capital reserve - realised

 

Gains or losses on investments realised in the year that have been recognised in the Income Statement are transferred to the capital reserve realised account on disposal. Furthermore, any prior unrealised gains or losses on such investments are transferred from the capital reserve unrealised account to the capital reserve realised account on disposal. This reserve is distributable.

 

Special distributable reserve

 

The total cost to the Company of the repurchase and cancellation of shares is represented in the special distributable reserve account. The special distributable reserve also represents capital dividends, capital investment management fees and the tax effect of capital items. This reserve is distributable.

 

Revenue reserve

 

The revenue reserve represents accumulated profits retained by the Company that have not been distributed to Shareholders as a dividend. This reserve is distributable.

 

3 Return per Ordinary Share

 

 

Six months ended

31 August 2023

The returns per share have been based on the following figures:

 

Weighted average number of Ordinary Shares

Revenue return

Capital return

 

 

146,815,611

£105,000

(£1,702,000)

Total return

(£1,597,000)

 

Directors' Responsibility Statement

The Directors confirm that, to the best of their knowledge:

 

? the Financial Statements for the six months ended 31 August 2023 have been prepared in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland;

 

? the Interim Management Report includes a fair review of the information required by DTR 4.2.7R in relation to the indication of important events during the first six months, and of the principal risks and uncertainties facing the Company during the second six months, of the year ending 29 February 2024; and

 

? the Interim Management Report includes adequate disclosure of the information required by DTR 4.2.8R in relation to related party transactions and any changes therein.

 

 

Other information

 

The NAV per Ordinary Share at 31 August 2023 has been calculated using the number of Ordinary Shares in issue of 148,542,742.

 

A full copy of the Interim Report and Financial Statements will be issued to Shareholders. Copies of this announcement will be available to the public at the office of Maven Capital Partners UK LLP, Kintyre House, 205 West George Street, Glasgow G2 2LW and at the registered office of the Company, 6th Floor, Saddlers House, 44 Gutter Lane, London EC2V 6BR.

 

Neither the content of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

By order of the Board

Maven Capital Partners UK LLP

Secretary

 

18 October 2023

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR BSBDGDUBDGXI
Date   Source Headline
26th Apr 20241:33 pmRNSUnaudited NAV & Proposed Final Dividend
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:47 pmRNSIssue of Equity
27th Mar 202410:34 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
21st Mar 20243:55 pmRNSStatement re Offer for Subscription
20th Mar 20243:44 pmRNSUnaudited Net Asset Value
8th Feb 202410:27 amRNSDirector/PDMR Shareholding
8th Feb 202410:26 amRNSDirector/PDMR Shareholding
8th Feb 202410:08 amRNSIssue of Equity
30th Jan 20245:09 pmRNSTransaction in Own Shares
17th Jan 20249:59 amRNSDirector/PDMR Shareholding
17th Jan 20249:57 amRNSIssue of Equity
15th Jan 20244:25 pmRNSUnaudited Net Value Asset
1st Dec 20239:39 amRNSIssue of Equity
24th Nov 202312:04 pmRNSStatement re Dividend Investment Scheme
9th Nov 20233:35 pmRNSResult of General Meeting
19th Oct 20234:51 pmRNSTransaction in Own Shares
18th Oct 20233:54 pmRNSHalf-year Report
13th Oct 20234:56 pmRNSPublication of a Prospectus
5th Oct 20234:39 pmRNSNet Asset Value and Interim Dividend
20th Jul 20234:32 pmRNSTransaction in Own Shares
14th Jul 20239:26 amRNSIssue of Equity
7th Jul 20234:17 pmRNSStatement re Dividend Investment Scheme
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
6th Jul 20233:37 pmRNSNet Asset Value
6th Jul 20231:06 pmRNSResult of AGM
7th Jun 20234:21 pmRNSAnnual Financial Report
2nd Jun 20239:39 amRNSIssue of Equity
1st Jun 202312:18 pmRNSNet Asset Value(s)
26th May 20233:53 pmRNSTransaction in Own Shares
24th May 202310:52 amRNSUnaudited NAV and Proposed Final Dividend
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
5th Apr 202312:33 pmRNSDirector/PDMR Shareholding
5th Apr 202312:26 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
3rd Mar 202310:37 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 202310:35 amRNSDirector/PDMR Shareholding
3rd Mar 20239:47 amRNSIssue of Equity
21st Feb 20234:39 pmRNSTransaction in Own Shares
6th Feb 20234:23 pmRNSNet Asset Value(s)
2nd Dec 20229:30 amRNSIssue of Equity
25th Nov 202212:36 pmRNSStatement re Dividend Investment Scheme
9th Nov 20222:34 pmRNSResult of General Meeting
4th Nov 202211:15 amRNSHalf-year Report
26th Oct 20223:50 pmRNSTransaction in Own Shares
14th Oct 20223:33 pmRNSNet Asset Value and Interim Dividend
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.